{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cohort+1+adjuvant&page=2",
    "query": {
      "intervention": "Cohort 1 adjuvant",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 163,
    "total_pages": 17,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cohort+1+adjuvant&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cohort+1+adjuvant&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-05T11:45:53.755Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01229644",
      "title": "Study of Crenolanib, a Selective and Potent Inhibitor of PDGFR, for the Treatment of Adult Gliomas",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioma"
      ],
      "interventions": [
        {
          "name": "Crenolanib (CP-868,596)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arog Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2011-04",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2018-07-05",
      "last_synced_at": "2026-10-05T11:45:53.755Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01229644"
    },
    {
      "nct_id": "NCT01439282",
      "title": "Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Estrogen Receptor Positive Tumor",
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "eribulin mesylate",
          "type": "DRUG"
        },
        {
          "name": "capecitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 77,
      "start_date": "2011-08",
      "completion_date": "2014-05",
      "has_results": true,
      "last_update_posted_date": "2023-06-22",
      "last_synced_at": "2026-10-05T11:45:53.755Z",
      "location_count": 23,
      "location_summary": "Tucson, Arizona • Orlando, Florida • Marietta, Georgia + 16 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Marietta",
          "state": "Georgia"
        },
        {
          "city": "Albany",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01439282"
    },
    {
      "nct_id": "NCT05313191",
      "title": "Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "CNS Cancer",
        "Head and Neck Cancer",
        "GI Cancer",
        "Gynecologic Cancer",
        "Prostate Cancer",
        "Thoracic Cancer",
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Pencil Beam Scanning Proton Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "The New York Proton Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1800,
      "start_date": "2022-01-24",
      "completion_date": "2028-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-10-05T11:45:53.755Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05313191"
    },
    {
      "nct_id": "NCT01938729",
      "title": "Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic Cholangiocarcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Intrahepatic Cholangiocarcinoma",
        "Peripheral Cholangiocarcinoma",
        "Cholangiolar Carcinoma",
        "Cholangiocellular Carcinoma) (ICC)"
      ],
      "interventions": [
        {
          "name": "Liver resection and placement of hepatic artery infusion pump",
          "type": "PROCEDURE"
        },
        {
          "name": "FLOXURIDINE",
          "type": "DRUG"
        },
        {
          "name": "DEXAMETHASONE",
          "type": "DRUG"
        },
        {
          "name": "GEMCITABINE",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2013-09-05",
      "completion_date": "2020-09-10",
      "has_results": false,
      "last_update_posted_date": "2020-09-11",
      "last_synced_at": "2026-10-05T11:45:53.755Z",
      "location_count": 5,
      "location_summary": "Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Rockville Centre",
          "state": "New York"
        },
        {
          "city": "Sleepy Hollow",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01938729"
    },
    {
      "nct_id": "NCT04683653",
      "title": "Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Endometrial Cancer"
      ],
      "interventions": [
        {
          "name": "Hypofractionated Radiation",
          "type": "RADIATION"
        },
        {
          "name": "Clinical Follow-Up and Assessments",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 100,
      "start_date": "2021-01-15",
      "completion_date": "2026-12-20",
      "has_results": false,
      "last_update_posted_date": "2026-09-10",
      "last_synced_at": "2026-10-05T11:45:53.755Z",
      "location_count": 5,
      "location_summary": "Atlanta, Georgia • Chicago, Illinois • Houston, Texas + 1 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04683653"
    },
    {
      "nct_id": "NCT00437502",
      "title": "A Phase I Study of Ovarian Cancer Peptides Plus GM-CSF and Adjuvant With Ovarian, Tubal or Peritoneal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Epithelial Ovarian, Tubal or Peritoneal Cancer"
      ],
      "interventions": [
        {
          "name": "tumor peptide vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Michael Morse, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 8,
      "start_date": "2007-03",
      "completion_date": "2010-01",
      "has_results": false,
      "last_update_posted_date": "2012-11-19",
      "last_synced_at": "2026-10-05T11:45:53.755Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00437502"
    },
    {
      "nct_id": "NCT02716246",
      "title": "Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "MPS IIIA",
        "Sanfilippo Syndrome",
        "Sanfilippo A",
        "Mucopolysaccharidosis III"
      ],
      "interventions": [
        {
          "name": "UX111",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prophylactic Immunomodulatory (IM) Therapy",
          "type": "DRUG"
        },
        {
          "name": "Optimized Prophylactic IM Therapy",
          "type": "DRUG"
        },
        {
          "name": "Adjuvant IM Therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Ultragenyx Pharmaceutical Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 36,
      "start_date": "2016-04-25",
      "completion_date": "2029-03",
      "has_results": false,
      "last_update_posted_date": "2026-09-22",
      "last_synced_at": "2026-10-05T11:45:53.755Z",
      "location_count": 2,
      "location_summary": "Columbus, Ohio • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02716246"
    },
    {
      "nct_id": "NCT04552886",
      "title": "Dendritic Cell Vaccination With Standard Postoperative Chemoradiation for the Treatment of Adult Glioblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "TH-1 Dendritic Cell Immunotherapy",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "The Cooper Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2021-10-11",
      "completion_date": "2023-12-01",
      "has_results": false,
      "last_update_posted_date": "2024-01-11",
      "last_synced_at": "2026-10-05T11:45:53.755Z",
      "location_count": 2,
      "location_summary": "Camden, New Jersey • Houston, Texas",
      "locations": [
        {
          "city": "Camden",
          "state": "New Jersey"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04552886"
    },
    {
      "nct_id": "NCT07027124",
      "title": "Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer",
        "High-risk Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Darolutamide",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Lupron",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Icahn School of Medicine at Mount Sinai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 40,
      "start_date": "2026-05-21",
      "completion_date": "2031-05-02",
      "has_results": false,
      "last_update_posted_date": "2026-06-16",
      "last_synced_at": "2026-10-05T11:45:53.755Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07027124"
    },
    {
      "nct_id": "NCT00052429",
      "title": "High-Dose Radiation Therapy Plus Chemotherapy in Treating Patients With Advanced Nose or Throat Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "adjuvant therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 25,
      "start_date": "2002-09",
      "completion_date": "2010-11",
      "has_results": true,
      "last_update_posted_date": "2018-01-09",
      "last_synced_at": "2026-10-05T11:45:53.755Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00052429"
    }
  ]
}